HCA vs JNJ

HCA Healthcare trades near its 52-week high with strong price momentum, up 37.9% over the past year and 225.1% over five years, reflecting sustained operational outperformance. The company delivered robust YoY earnings growth of 42.6%, supported by consistent quarterly beats—21 of the last 25 quarters—and accelerating revenue growth at 9.6%. Despite a premium valuation relative to some peers, HCA’s profitability metrics, including a 15.47% operating margin and 12.20% ROA, are industry-leading and justify the multiple. Analysts are aligned with a 'buy' recommendation and a $477.57 target price, implying modest upside, while insider selling remains limited in volume and likely routine.

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.